¼¼°èÀÇ ¹ÙÀÌ¿À´Ð ÀÇÁö ½ÃÀå
Bionic Prosthetics
»óǰÄÚµå : 1745008
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 243 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,136,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,408,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹ÙÀÌ¿À´Ð ÀÇÁö ½ÃÀåÀº 2030³â±îÁö 27¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 18¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹ÙÀÌ¿À´Ð ÀÇÁö ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 7.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 27¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÏÁö º¸Ã¶Àº CAGR 6.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 17¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »óÁö º¸Ã¶ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 8.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 6,480¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹ÙÀÌ¿À´Ð ÀÇÁö ½ÃÀåÀº 2024³â¿¡ 4¾ï 6,480¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 7.3%·Î 2030³â±îÁö 4¾ï 3,700¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 6.7%¿Í 6.4%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 6.1%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿À´Ð ÀÇÁö ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö ¹ÙÀÌ¿À´Ð ÀÇÁ·ÀÌ Ã·´Ü À̵¿¼º, ±â´É ȸº¹, ½Å°æ ÀûÀÀ ÀçȰ¿¡¼­ Àΰ£°ú ±â°èÀÇ ÅëÇÕÀ» ÀçÁ¤ÀÇÇϴ°¡?

¹ÙÀÌ¿À´Ð ÀÇÁ·Àº Áöü Àå¾Ö³ª ¼±ÃµÀû Àå¾Ö¸¦ °¡Áø »ç¶÷µéÀÇ ¿îµ¿ ±â´É, ¼ÕÀçÁÖ, °¨°¢ Çǵå¹éÀ» ȸº¹ÇÒ ¼ö ÀÖ´Â º¸Á¶ ±â¼ú ºÐ¾ßÀÇ Çõ½ÅÀûÀÎ ¹ßÀüÀ» »ó¡ÇÕ´Ï´Ù. »ýü¿ªÇÐ °øÇÐ, ·Îº¿ °øÇÐ, ½Å°æ ÀÎÅÍÆäÀ̽º ½Ã½ºÅÛ, ÷´Ü Àç·á °úÇÐÀ» °áÇÕÇÏ¿© ¹ÙÀÌ¿À´Ð ÀÇÁ·Àº ±âÁ¸ ÀÇÁ·¿¡ ºñÇØ »ç¿ëÀÚ¿¡°Ô ´õ ³ªÀº Á¦¾î¼º, ¿îµ¿ ¹üÀ§ ¹× ¹ÝÀÀ¼ºÀ» Á¦°øÇÕ´Ï´Ù. ÇコÄɾî¿Í ¸ÞīƮ·Î´Ð½ºÀÇ À¶ÇÕÀ» ÅëÇÑ °³ÀÎÈ­µÈ ÀçȰÀ» ¹Ý¿µÇÏ¿©, ÀÌ·¯ÇÑ Àåºñ´Â Àΰ£ ½Å°æ±ÙÀ° ½Ã½ºÅÛÀÇ È®ÀåÀ¸·Î °£Áֵǰí ÀÖ½À´Ï´Ù.

±â´ÉÀû ÀÚ¸³, »îÀÇ Áú Çâ»ó, Á¤¹ÐÇÑ À̵¿¼º¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁü¿¡ µû¶ó »óÁö ¹× ÇÏÁö ÀÇÁ·ÀÇ °¢ ºÐ¾ß¿¡¼­ÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À´Ð ÀÇÁ·Àº ±ÙÀüµµ(EMG)¿Í ³ú-ÄÄÇ»ÅÍ ÀÎÅÍÆäÀ̽º(BCI)¸¦ ÅëÇÑ Á÷°üÀûÀÎ µ¿ÀÛ Á¦¾î¸¦ °¡´ÉÇÏ°Ô Çϱâ À§ÇØ ¼¾¼­, ¸¶ÀÌÅ©·ÎÇÁ·Î¼¼¼­, ½Ç½Ã°£ ½Åȣ󸮸¦ ³»ÀåÇϰí ÀÖ½À´Ï´Ù. »ç¿ëÀÚ´Â Àâ±â, ȸÀü, ±âº¹ÀÌ ÀÖ´Â ÁöÇü¿¡¼­ÀÇ º¸Çà µî º¹ÀâÇÑ ´Ù°üÀý µ¿ÀÛÀ» ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ã˰¢ Çǵå¹éÀ» ÅëÇÕÇÏ¿© °¨°¢À» ½Ã¹Ä·¹À̼ÇÇϰí Çൿ°ú ÀÇ½Ä »çÀÌÀÇ Çǵå¹é ·çÇÁ¸¦ ´Ý´Â ½Ã½ºÅÛµµ ÀÖ½À´Ï´Ù.

¼¼°è Àα¸ Åë°èÇÐÀû º¯È­¿¡ µû¶ó ¿Ü»ó, ´ç´¢º´, Ç÷°ü ÁúȯÀ¸·Î ÀÎÇÑ »çÁö Àý´Ü ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àå±âÀûÀΠȯÀÚ Ä¡·á °æ·Î¿¡¼­ ¹ÙÀÌ¿À´Ð ÀÇÁ·Àº Àü·«Àû Á߿伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °ø°ø ÀÇ·á ½Ã½ºÅÛ, ÀçÇⱺÀÎ ÀÇ·á ÇÁ·Î±×·¥, ¹Î°£ º¸Çè»çµéÀº ÀÇÁ¸¼º °¨¼Ò, °í¿ë °¡´É¼º Çâ»ó, ºÎµ¿¼º °ü·Ã ÀÌÂ÷Àû ÇÕº´Áõ ÃÖ¼ÒÈ­ µî ÷´Ü ÀÇÁ·ÀÇ Ä¡·áÀû, °æÁ¦Àû °¡Ä¡¸¦ Á¡Á¡ ´õ ¸¹ÀÌ ÀνÄÇϰí ÀÖ½À´Ï´Ù.

¼¾¼­ ±â¼ú, AI ÅëÇÕ, ½Å°æ ÀûÀÀÇü ÀÎÅÍÆäÀ̽º´Â ¹ÙÀÌ¿À´Ð ÀÇÁ·ÀÇ ±â´É°ú »ç¿ëÀÚ °æÇèÀ» ¾î¶»°Ô Çâ»ó½Ãų ¼ö ÀÖÀ»±î?

¼¾¼­ÀÇ ¼ÒÇüÈ­¿Í AI¸¦ Ȱ¿ëÇÑ ½ÅÈ£ 󸮴 ¹ÙÀÌ¿À´Ð ÀÇÁ·ÀÌ »ç¿ëÀÚÀÇ Àǵµ¸¦ ÇØ¼®ÇÏ°í ¹ÝÀÀÇÏ´Â ¹æ½Ä¿¡ Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ³»ÀåµÈ °ü¼º ÃøÁ¤ ÀåÄ¡(IMU), ¾Ð·Â ¼¾¼­, »ýü Àü±â °¨Áö±â¸¦ ÅëÇØ »çÁöÀÇ À§Ä¡, º¸Çà ¿ªÇÐ, ±ÙÀ° Ȱµ¿À» ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÅÈ£´Â ¿îµ¿ ¹ÝÀÀÀ» ÇнÀÇÏ°í °³¼±ÇÏ´Â ÀûÀÀÇü ¾Ë°í¸®Áò¿¡ ÀԷµǾî ÀÏ»óÀûÀÎ ÀÛ¾÷°ú ´Ù¾çÇÑ ÁöÇü¿¡¼­ º¸´Ù ¿øÈ°ÇÑ Àüȯ°ú º¸´Ù °³ÀÎÈ­µÈ ¸ðºô¸®Æ¼ °æÇèÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

÷´Ü ¹ÙÀÌ¿À´Ð ÀÇÁ·Àº ÇöÀç °³º° ±ÙÀ°ÀÇ ¹ßÈ­ ÆÐÅÏÀ» ÀνÄÇÏ´Â ¸Ó½Å·¯´× ¸ðµ¨À» Ȱ¿ëÇÏ¿© ¹Ð¸®ÃÊ ´ÜÀ§·Î ÀÛµ¿À» Á¶Á¤ÇÔÀ¸·Î½á ÀåÄ¡ÀÇ ¹ÝÀÀ¼º°ú »ç¿ëÀÚ ÆíÀǼºÀ» Çâ»ó½Ã۰í, AI ±â¹Ý º¸Á¤ ½Ã½ºÅÛÀ» ÅëÇØ ÀÓ»óÀÇÀÇ ¼öµ¿ Á¶Á¤ Çʿ伺À» ÁÙÀ̰í, ´õ ºü¸¥ Âø¿ë°ú »ç¿ëÀÚ ÀûÀÀÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. º¸´Ù ºü¸¥ Âø¿ë°ú »ç¿ëÀÚ ÀûÀÀÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, Ŭ¶ó¿ìµå ±â¹Ý ¼ÒÇÁÆ®¿þ¾î ¾÷µ¥ÀÌÆ®¿Í ¿ø°Ý ÃøÁ¤À» ÅëÇØ ¿ø°ÝÀ¸·Î ¼º´É ÃÖÀûÈ­ ¹× ¿¹Ãø À¯Áöº¸¼ö°¡ °¡´ÉÇÏ¿© ¼­ºñ½º ºñ¿ëÀ» Àý°¨ÇÏ°í ½Ã½ºÅÛ ¼ö¸íÀ» ¿¬ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

½Å°æ ÀûÀÀÇü ÀÎÅÍÆäÀ̽º´Â Àΰ£°ú ÀÇÁ·ÀÇ ÅëÇÕÀÇ °æ°è¸¦ º¸¿©ÁÖ´Â °ÍÀ¸·Î, Á÷Á¢ ½Å°æ ÀÚ±Ø, °ñÀ¯Âø, ÇÇÁú ÀÓÇöõÆ®¸¦ Ȱ¿ëÇÏ¿© º¸´Ù ¿øÈ°ÇÑ Á¦¾î¿Í °¨°¢ Çǵå¹é ·çÇÁ¸¦ »ý¼ºÇÕ´Ï´Ù. ¿îµ¿ ¸í·ÉÀ» ÇØµ¶ÇÒ »Ó¸¸ ¾Æ´Ï¶ó Ã˰¢°ú °íÀ¯ °¨°¢ ½ÅÈ£¸¦ »ç¿ëÀÚÀÇ ½Å°æ°è·Î µÇµ¹·Á º¸³»´Â ¾ç¹æÇâ ÀÇÁ· ½Ã½ºÅÛ¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ÀÇÁ·°ú Àΰ£ Áõ°­ÀÇ °æ°è°¡ ¸ðÈ£ÇØÁö°í ÀÖÀ¸¸ç, ½ÃÀåÀº ÁøÁ¤ÇÑ Àΰ£°ú ±â°èÀÇ °ø»ý ½Ã½ºÅÛÀ» ÇâÇØ ³ª¾Æ°¡°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À´Ð ÀÇÁ·ÀÇ »ó¿ëÈ­¸¦ ÃËÁøÇÏ´Â ÇコÄÉ¾î ½Ã½ºÅÛ, ÃÖÁ¾ »ç¿ëÀÚ ºÎ¹®, Çõ½Å »ýŰè´Â?

¹ÙÀÌ¿À´Ð ÀÇÁ·¿¡ ´ëÇÑ ¼ö¿ä´Â ÀçÇⱺÀÎ, ¿Ü»ó »ýÁ¸ÀÚ, ´ç´¢º´¼º Àý´ÜÀÚ »çÀÌ¿¡¼­ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À̵éÀº ±¹°¡¿Í º¸Çè»çÀÇ Áö¿øÀ» ¹Þ¾Æ °í±Þ À̵¿¼º ÀåÄ¡¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼Ò¾Æ ¹× ¼±Ãµ¼º »çÁö °á¼Õ ȯÀڵ鵵 ¸ðµâÇü, ¼ºÀå ÀûÀÀÇü, ¼Ò¾Æ Àü¿ë ±ÙÀüµµ ½Ã½ºÅÛÀÌ ½ÃÀå¿¡ ÁøÀÔÇÔ¿¡ µû¶ó ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ ±×·ìÀÌ µÇ°í ÀÖ½À´Ï´Ù. °í¼Òµæ Áö¿ª¿¡¼­´Â °í·ÉÈ­°¡ ÁøÇàµÇ°í ÀÖÀ¸¸ç, °í·É Àý´ÜÀÚÀÇ º¸ÇàÀ» °³¼±ÇÏ°í ³«»óÀ» ¿¹¹æÇϱâ À§ÇØ ÇÏÁö ¹ÙÀÌ¿À´Ð½ºÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â °­·ÂÇÑ Á¤ºÎ ÀÚ±Ý, ±¹¹æ ºÎ¹®°úÀÇ Á¦ÈÞ, ¹Î°ü ¿¬±¸ Çù·Â¿¡ ÈûÀÔ¾î µµÀÔ ¹× Çõ½Å Ãø¸é¿¡¼­ ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº MDR¿¡ µû¸¥ źźÇÑ »óȯ Á¦µµ¿Í ÀÇ·á±â±â ½ÂÀÎ °æ·Î¸¦ ÅëÇØ ½ÃÀåÀ» µû¶óÀâ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ƯÈ÷ ÀϺ», Çѱ¹, È£ÁÖ´Â Àα¸ °í·ÉÈ­, ÀçȰ ÀÎÇÁ¶óÀÇ ¼ºÀå, ÀÇ·á ±â¼ú ·Îº¿¿¡ ´ëÇÑ ÅõÀÚ·Î ÀÎÇØ ÀáÀç·ÂÀÌ ³ôÀº Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ÁßÁø±¹¿¡¼­´Â ºñ¿ë¿¡ ¹Î°¨ÇÑ ÇコÄÉ¾î ½Ã½ºÅÛ¿¡ ¸ÂÃá È®Àå °¡´ÉÇÑ ¸ðµâÇü ¹ÙÀÌ¿À´Ð½º ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

Çмú±â°ü, ÀçȰ¼¾ÅÍ, ÀÇ·á±â¼ú ±â¾÷ÀÌ °áÇÕµÈ ¿¬±¸°³¹ß »ýŰ谡 Á¦Ç° °³¹ß°ú ÀÓ»ó °ËÁõÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. º¥Ã³±â¾÷ÀÌ Áö¿øÇÏ´Â ½ºÅ¸Æ®¾÷, ±¹¹æºÎ°¡ Áö¿øÇÏ´Â Çõ½Å Çãºê, ½Å°æ¿ªÇÐ ¹× »ýü°øÇÐÀÇ ´ÙÇÐÁ¦Àû ¿¬±¸°¡ °æ·® ¼ÒÀç, ÀûÀÀÇü Á¦¾î ¾Ë°í¸®Áò, Àΰ£-±â°è °£ Åë½Å ÇÁ·ÎÅäÄÝÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. »ó¿ëÈ­ ±Ô¸ð°¡ È®´ëµÊ¿¡ µû¶ó Á¦Á¶¾÷üµéÀº ¸ðµâÈ­, ºÎǰ ȣȯ¼º, Ŭ¶ó¿ìµå ±â¹Ý Áö¿ø ¸ðµ¨¿¡ ÁßÁ¡À» µÎ¾î ºñ¿ëÀ» Àý°¨ÇÏ°í ÆÇ¸Å ÈÄ ¼­ºñ½º °¡´É¼ºÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À´Ð ÀÇÁ· ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

÷´Ü º¸Á¶ ±â¼úÀÌ ÀÚÀ²¼º ȸº¹, ÀçȰ ¼º°ú Çâ»ó, Àΰ£°ú ±â°èÀÇ »óÈ£ÀÛ¿ë °æ°è¸¦ ÀçÁ¤ÀÇÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® ÀâÀ¸¸é¼­ ¹ÙÀÌ¿À´Ð ÀÇÁ· ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ÀÇÁ·À» ±â°èÀû º¸»ó¿¡¼­ Áö´ÉÇü »ýü ¹ÝÀÀ¿¡ ÀÇÇÑ °­È­·Î À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â »çÁö °á¼Õ ¹ß»ý·ü Áõ°¡, º¸Çè Àû¿ë ¹üÀ§ È®´ë, ½Å°æ±Ù ÀÎÅÍÆäÀ̽º ±â¼ú ¹ßÀü, AI ±â¹Ý ÀûÀÀÇü Á¦¾î ½Ã½ºÅÛ, ÀÇ·á ±â¼ú Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æº¸Ã¶°ú »ýü ÅëÇÕ ·Îº¿°øÇÐÀÌ ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ´Â °Íµµ Àå±âÀûÀÎ ½ÃÀå ÀáÀç·ÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

ÀÇÁ·ÀÌ ¼öµ¿Àû Áö¿ø¿¡¼­ ÀÎüÀÇ Áö´ÉÇü È®ÀåÀ¸·Î ÁøÈ­ÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À´Ð ÀÇÁ·Àº »ý¹° ÀÇÇÐ Çõ½ÅÀÇ ´ÙÀ½ °³Ã´Áö°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ÇÏÁö, »óÁö, ±âŸ Á¦Ç° À¯Çü), Å×Å©³î·¯Áö(¼öµ¿, ü µ¿, ±ÙÀü Å×Å©³î·¯Áö, Targeted Muscle Reinnervation, °ñÀ¯Âø(Osseointegration), LUKE Arm), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø£¦Å¬¸®´Ð, ÀçȰġ·á¼¾ÅÍ, Àü¹® Ŭ¸®´Ð, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 48°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bionic Prosthetics Market to Reach US$2.7 Billion by 2030

The global market for Bionic Prosthetics estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Lower Limb Prosthetics, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Upper Limb Prosthetics segment is estimated at 8.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$464.8 Million While China is Forecast to Grow at 7.3% CAGR

The Bionic Prosthetics market in the U.S. is estimated at US$464.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$437.0 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Bionic Prosthetics Market - Key Trends & Drivers Summarized

Why Are Bionic Prosthetics Redefining Human-Machine Integration in Advanced Mobility, Functional Restoration, and Neuroadaptive Rehabilitation?

Bionic prosthetics represent a transformative advancement in the field of assistive technologies, enabling the restoration of motor function, dexterity, and sensory feedback for individuals with limb loss or congenital disabilities. By combining biomechanical engineering, robotics, neural interface systems, and advanced material science, bionic limbs offer users greater control, range of motion, and responsiveness compared to traditional prosthetics. These devices are increasingly regarded as extensions of the human neuromuscular system, reflecting the convergence of healthcare and mechatronics in personalized rehabilitation.

The rising demand for functional independence, improved quality of life, and precision mobility is fueling adoption across upper and lower limb prosthetic segments. Bionic prosthetics incorporate sensors, microprocessors, and real-time signal processing to enable intuitive movement control via electromyography (EMG) or brain-computer interfaces (BCIs). Users can perform complex, multi-joint movements such as grasping, rotating, or walking on uneven terrain, while some systems integrate haptic feedback to simulate sensory perception-closing the feedback loop between action and awareness.

As global demographics shift and the incidence of limb amputation from trauma, diabetes, and vascular disease increases, bionic prosthetics are gaining strategic importance in long-term patient care pathways. Public health systems, veterans' healthcare programs, and private insurers are increasingly recognizing the therapeutic and economic value of advanced prosthetics in reducing dependency, enhancing employability, and minimizing secondary complications related to immobility.

How Are Sensor Technologies, AI Integration, and Neuroadaptive Interfaces Enhancing Bionic Prosthetic Functionality and User Experience?

Sensor miniaturization and AI-enabled signal processing are revolutionizing how bionic prosthetics interpret and respond to user intent. Embedded inertial measurement units (IMUs), pressure sensors, and bioelectrical detectors allow devices to track limb position, gait dynamics, and muscle activity in real time. These signals are fed into adaptive algorithms that learn and refine movement responses, allowing for smoother transitions and more personalized mobility experiences across daily tasks and varying terrains.

Advanced bionic limbs now utilize machine learning models that recognize individual muscle firing patterns and adjust actuation in milliseconds, improving device responsiveness and user comfort. AI-driven calibration systems are reducing the need for manual tuning by clinicians, enabling faster onboarding and user adaptation. Cloud-based software updates and telemetry are also enabling remote performance optimization and predictive maintenance, lowering service costs and enhancing system longevity.

Neuroadaptive interfaces represent the frontier of human-prosthetic integration, leveraging direct nerve stimulation, osseointegration, and cortical implants to create more seamless control and sensory feedback loops. Clinical trials are underway for bi-directional prosthetic systems that not only decode motor commands but also send tactile or proprioceptive signals back to the user’s nervous system. These advancements are blurring the line between prosthetics and augmentation-pushing the market toward truly symbiotic human-machine systems.

Which Healthcare Systems, End-User Segments, and Innovation Ecosystems Are Driving Commercialization of Bionic Prosthetics?

Demand for bionic prosthetics is rising among military veterans, trauma survivors, and diabetic amputees-segments that often receive state or insurer-supported access to high-end mobility devices. Pediatric and congenital limb difference populations are also becoming key end-user groups, as modular, growth-adaptive designs and pediatric-specific myoelectric systems enter the market. Aging populations in high-income regions are driving increased use of lower-limb bionics to improve ambulation and prevent falls in elderly amputees.

North America leads the market in terms of adoption and innovation, supported by strong government funding, defense sector partnerships, and public-private research collaborations. Europe follows closely with robust reimbursement frameworks and medical device approval pathways under MDR. Asia-Pacific, particularly Japan, South Korea, and Australia, is emerging as a high-potential region, backed by aging demographics, growing rehabilitation infrastructure, and investments in medtech robotics. Meanwhile, middle-income countries are exploring scalable, modular bionics tailored for cost-sensitive healthcare systems.

R&D ecosystems combining academia, rehabilitation centers, and medtech companies are accelerating product development and clinical validation. Venture-backed startups, defense-funded innovation hubs, and cross-disciplinary research in neuromechanics and biomedical engineering are driving breakthroughs in lightweight materials, adaptive control algorithms, and human-machine communication protocols. As commercialization scales, manufacturers are focusing on modularity, component interchangeability, and cloud-based support models to lower costs and improve post-sale serviceability.

What Are the Factors Driving Growth in the Bionic Prosthetics Market?

The bionic prosthetics market is expanding as advanced assistive technologies become integral to restoring autonomy, enhancing rehabilitation outcomes, and redefining the boundaries of human-machine interaction. These systems are reshaping the prosthetics landscape from mechanical compensation to intelligent, bio-responsive enhancement.

Key growth drivers include rising incidence of limb loss, expanding reimbursement coverage, advances in neuromuscular interface technology, AI-enabled adaptive control systems, and growing investments in medtech innovation. Broader acceptance of neuroprosthetics and bio-integrated robotics is also reinforcing long-term market potential.

As prosthetics evolve from passive support to intelligent extensions of the human body, could bionic limbs become the next frontier in biomedical innovation-positioned not only to restore function but to elevate human capability through seamless integration with cognitive and physical systems?

SCOPE OF STUDY:

The report analyzes the Bionic Prosthetics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Lower Limb, Upper Limb, Other Product Types); Technology (Passive, Body-Powered, Myoelectric Technology, Targeted Muscle Reinnervation, Osseointegration, LUKE Arm); End-Use (Hospitals & Clinics, Rehabilitation Centers, Specialty Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 48 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â